Company / PP&E (Net)
Gain Therapeutics, Inc. PP&E (Net) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$103.6K
FY2024
5-year range
$103.6K / $144.4K
FY2021-FY2024
Trend
-17.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $144,379 to $103,619 over the past 2 years.
Based on SEC 10-K filings.
$103,619 in FY2024 with a 3-year CAGR of -0.8%.
Declined from $144,379 to $103,619 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -0.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -0.8%, indicating a declining trend.
- In FY2024, pp&e (net) decreased 17.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | $103.6K | -17.7% |
| FY2023 | $126.0K | -12.8% |
| FY2022 | $144.4K | +36.2% |
| FY2021 | $106.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026